metastatic brain cancer

metastatic brain cancer

A brain tumour arising from metastatic malignancy.

Primary sites
Lung, breast, colon, kidney, melanoma.
References in periodicals archive ?
under the mistaken impression that he was dying of metastatic brain cancer.
Washington, June 9 (ANI): In what may become a new drug target for metastatic brain cancer, scientists from The Scripps Research Institute have discovered a molecular mechanism that plays a pivotal role in controlling cancer growth in the brain.
Fancifully named after the Lone Star State, a light-sensitive drug called texaphyrin has shown success in treating metastatic brain cancer.
Metastatic brain cancer is one of the most deadly forms of cancer, with most of its victims dying within a year of diagnosis.
This in-licensing augments our oncology clinical pipeline to address metastatic brain cancer, a large global unmet medical need.
Primary brain cancer, or glioma, starts in the brain and metastatic brain cancer starts somewhere else in the body and moves to the brain.
His commitment to advance cancer research is truly incredible and is matched only by his extraordinary ability to reach and inspire other patients and families living with cancer with his personal triumph over with metastatic brain cancer.
For recurrent malignant gliomas and metastatic brain cancer, treatment options for patients are limited and prognoses are dismal.
We are also planning for a pediatric phase I/II trial, exploring the possibility of administering intrathecally for metastatic brain cancer, and moving forward with an oral form.
It is highly encouraging to see that ANG1005 has shown the potential to be effective in metastatic brain cancers and against drug resistant tumors, that are highly aggressive and have few treatment options," commented Jan Drappatz, MD, Center for Neuro-Oncology at Dana-Farber Cancer Institute, Department of Neurology at Brigham and Women's Hospital, and, Harvard Medical School, and lead investigator for Boston-area study centers.
In addition, brain pharmacokinetic data demonstrates that CUDC-305 is highly brain penetrable suggesting that the compound may have potential advantages for the treatment of primary or metastatic brain cancers.
RTA 744 is a novel anti-cancer drug that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.